US20010047012A1 - Combination therapy for treating glaucoma - Google Patents
Combination therapy for treating glaucoma Download PDFInfo
- Publication number
- US20010047012A1 US20010047012A1 US09/267,966 US26796699A US2001047012A1 US 20010047012 A1 US20010047012 A1 US 20010047012A1 US 26796699 A US26796699 A US 26796699A US 2001047012 A1 US2001047012 A1 US 2001047012A1
- Authority
- US
- United States
- Prior art keywords
- iop
- lowering agent
- alkyl
- glutamate
- glutamate antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)C(B)C.CC.CC.CC.CC.CC.CC.CC.CC1=CC2(=CC=C1)CCSC2.CC1=CC2=C(C=C1)N(C)C(=O)C2.CC1=CC=CC=C1.CNCC([Y])CC1=CC=CC=C1.[Y]C1(CC2=CC=CC=C2)CNC1 Chemical compound *C(*)C(B)C.CC.CC.CC.CC.CC.CC.CC.CC1=CC2(=CC=C1)CCSC2.CC1=CC2=C(C=C1)N(C)C(=O)C2.CC1=CC=CC=C1.CNCC([Y])CC1=CC=CC=C1.[Y]C1(CC2=CC=CC=C2)CNC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This case is a continuation in part of U.S. Ser. No. 08/919,882, filed Aug. 28, 1997, which is a continuation of U.S. Ser. No. 08/560,055, filed Nov. 17, 1995.
- The present invention relates generally to the field of ophthalmology. In particular, the invention relates to the treatment of glaucoma using a combination of a glutamate antagonist to preserve visual field and an intraocular pressure lowering compound.
- Although the underlying causes of glaucoma are not well understood at this time, glaucoma is characterized by damage to the optic nerve, accompanied by a decrease in the normal visual field. One early warning sign of possible glaucomatous visual field loss is elevated intraocular pressure (“IOP”). In fact, glaucoma has historically been treated by medically and /or surgically lowering elevated IOP, for example, by the administration of IOP-lowering agents such as miotics, α and α/β adrenergic agonists, beta-blockers, and carbonic anhydrase inhibitors. However, factors other than IOP may play a role in the occurrence of visual field loss. Degeneration of retinal ganglion cells may be related to ischemia or mechanical distortion of the nerve fibers as they exit through the optic nerve head or from pathological perturbations of the retina.
- There has been a growing interest in retinal dysfunction as a contributor to the glaucomatous process. Retinal dysfunction, and hence pathology, may be related to ischemia or excitotoxicity. Excitotoxicity is neuronal injury due to excessive excitatory amino acid (“EAA”) stimulation. In the inner retina, glutamate is the major EAA that permits the bipolar and amacrine cells to communicate with the ganglion cell. In the central nervous system, excitotoxicity results from hypoxia, ischemia, hypoglycemia or trauma. (See, for example, Beal, M. F., “Mechanisms of excitotoxicity in neurologic diseases,”FASEB J., 6:3338-3344 (1992); and Choi, D. W., “Excitotoxic cell death,” J. Neurobiol., 23:1261-1276 (1992).) Toxicity to the inner retina has been observed following intravitreal injection of EAAs following application of EAAs to the isolated animal retina or from exogenously applied glutamate to retinal ganglion cells in culture. See generally, Sattayasai, et al., “Morphology of quisqualate-induced neurotoxicity in the chicken retina,” Invest. Ophthalmol. Vis. Sci., 28:106-117 (1987); Tung et al., “A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick, Visual Neurosci., 4:217-223 (1990); Sisk et al., “Histological changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate,” Graefe's Arch. Clin. Exp. Ophthalmol., 223:250-258 (1985); Siliprandi et al., “N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina,” Visual Neurosci., 8:567-573 (1992); Reif-Lehrer et al., “Effects of monosodium glutamate on chick embryo retina in culture,” Invest. Ophthalmol. Vis. Sci., 14(2):114-124 (1975); Blanks, J. C., “Effects of monosodium glutamate on the isolated retina of the chick embryo as a function of age: A morphological study,” Exp. Eye Res., 32:105-124 (1981); Olney et al., “The role of specific ions in glutamate neurotoxicity,” Neurosci. Lett., 65:65-71 (1986); Olney et al., “The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics,” Neurosci. Lett 68:29-34 (1986); Price et al., “CNQX potently and selectively blocks kainate excitotoxicity in the chick embryo retina,” Soc. Neurosci. Abst., 14:418 (1988); David et al., “Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas by anoxia and extracellular high potassium,” Exp. Eve Res., 46:657-662 (1988); Caprioli et al., “Large retinal ganglion cells are more susceptible to excitotoxic and hypoxic injury than small cells Invest. Ophthalmol. Vis. Sci., 34(Suppl):1429 (1993); Cummins et al., “Electrophysiology of cultured retinal ganglion cells to investigate basic mechanics of damage,” Glaucoma Update IV, 59-65 (1991); and Sucher et al., “N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro,” J. Neurosci., 11(4):966-971 (1991).
- EAA receptors have been characterized as metabotropic or ionotropic. Activation of a metabotropic receptor affects cellular processes via G-proteins; whereas ionotropic receptors affect the translocation of mono- and divalent cations across the cell membrane. There are at least three ionotropic receptors that have been named for the agonist that preferentially stimulates the receptor. These receptors have been classified as: N-methyl-D-aspartate (NMDA); kainate; and AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid). These EAA receptors are differentially distributed to specific cells in the retina. (See, for example, Massey, S., “Cell types using glutamate as a neurotransmitter in the vertebrate retina,” N. N. Osborne and G. J. Chader (Eds.)Progress in Retinal Research, Ch. 9, Pergammon Press: Oxford, 399-425 (1990); and Miller et al., “Excitatory amino acid receptors in the vertebrate retina,” in Retinal Transmitters and Modulators: Models for the Brain, (W. W. Morgan, Ed.) CRC Press, Inc., Boca Raton, II:123-160 (1985).) The localization of such receptors would account for the pathologies associated with glaucoma or inner retinal ischemia. For example, death of the retinal ganglion cell has to a large part been attributed to the NMDA receptor. (See, for example, Sucher et al., “N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in retinal ganglion cells in vitro,” J. Neurosci., 11(4):966-971 (1991).). Thus, antagonists of the NMDA receptor are neuroprotective; however, not all antagonists of the diversely distributed EAA receptors are neuroprotective to the inner retina through antagonism of the NMDA receptor, Zeevalk et al., “Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity,” Brain Res., 522:135-139 (1990)), and many of these EAA antagonists have significant CNS side-effects and are therefore not suitable for treating these degenerative diseases of the eye.
- The present invention is directed to the use of a glutamate antagonist and an IOP controlling agent, dosed separately or in combination for the treatment of persons suffering from glaucoma or ocular hypertension.
- The present invention involves the use of two types of agents to treat glaucoma and ocular hypertension. One agent is an IOP-lowering agent directed at preventing the damage to retinal ganglion cells brought on by mechanical, circulatory, and other poorly understood factors related to elevated IOP. The second agent is a glutamate antagonist used to prevent further damage to ganglion cells and optic nerve fibers from excitotoxicity.
- As used herein the term glutamate antagonist means an antagonist of the NMDA receptor channel complex. NMDA receptor antagonists include channel blockers (agents that operate uncompetitively to block the NMDA receptor channel); receptor antagonists (agents that compete with NMDA or glutamate at the NMDA binding site); and agents acting at the glycine coagonist site or any of several modulation sites (e.g., zinc, magnesium, redox, or polyamine sites).
-
- Y,X═OII,II
- m=0-3
- n,p=1,2
- R1═H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy or when R2═OH or methoxy in the 4-position and R3═H then R1=hydroxymethyl, carbamoyl, or C1-4 alkoxycarbonyl;
- R2═H, halogen, C1-4 alkyl, OH, C1-4 alkoxyl;
- R3, R4═H, C1-4 alkyl; and
- R5═H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy.
- These compounds include all isomers and pharmaceutically acceptable salts.
- Other preferred compounds include: amantadine, budipine, felbamate, cerestat (CNS-1102, aptiganel), dextromethorphan, dexanabinol, ADCI, araxins, CNS-5161, B111-277CL, WAY-126251 (see Drug News Perspect 11(9), November 1998), memantine, and other compounds disclosed in WO 94/13275 to the extent they are suitable for chronic administration.
- In general, at least one of the compounds of this invention are administered orally with daily dosage of these compounds ranging between 0.01 and 500 milligrams. The preferred total daily dose ranges between 1 and 100 milligrams. Non-oral administration, such as, intravitreal, topical ocular, transdermal patch, parenteral, intraocular injection, or subconjunctival routes may require an adjustment of the total daily dose necessary to provide a therapeutically effect amount of the compound.
- The compounds can be incorporated into various types of ophthalmic formulations for topical delivery to the eye. They may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions. Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. The ophthalmic solutions may contain a thickener, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl-pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
- If dosed topically, the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8. The compounds will normally be contained in these formulations in an amount 0.001% to 5% by weight, but preferably in an amount of 0.01% to 2% by weight. Thus, for topical presentation, 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the routine discretion of a skilled clinician.
- The preferred compound, eliprodil, is orally bioavailable, demonstrates a low incidence of adverse effects upon administration, and effectively crosses the blood-brain barrier (Drugs of the Future, 1994, 19, 905-909) indicating that effective concentrations are expected in the target tissue, the retina. The compound is described in U.S. Pat. No. 4,690,931, the contents of which are incorporated herein by reference.
- The IOP-lowering agents useful in the present invention include all presently known IOP-lowering pharmaceuticals, including, but not limited to, miotics (e.g., pilocarpine, carbachol, and acetylcholinesterase inhibitors); α and α/β adrenergic agonists (e.g., epinephrine, dipivalylepinephrine, para-amino clonidine and brimonidine); beta-blockers (e.g., betaxolol, S-betaxolol, levobunolol, carteolol, and timolol); prostaglandins and their analogues and derivatives, such as, compounds disclosed in U.S. Pat. Nos. 4,599,353; 5,093,329; and 5,321,128 and in European Patent Nos. 0215 860 B1 and 0 299 914 B1; and carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide, and ethoxzolamide, and compounds disclosed in U.S. Pat. Nos. 5,153,192; 5,240,923; 5,378,703; and 4,797,413) and ocular hypertensive lipids, such as those compounds (neutral replacement of the carboxylic acid group of prostaglandin F2α e.g. AGN 192024) described in IOVS, Mar. 15, 1998, Vol. 39, No. 4; WO 97/30710, U.S. Pat. Nos. 5,238,961; 5,262,437; 5,328,933; 5,352,708; 5,312,842; 5,552,434; 5,545,665; 5,688,819. The preferred IOP-lowering agents are: timolol, betaxolol, S-betaxolol levobunolol, carteolol, pilocarpine, carbachol, epinephrine, dipivalyl epinephrine-αmethyl dipivalylepinephrine, brinzolamide, dorzolamide, unoprostone, latanoprost, travoprost, apraclonidine, and brimonidine.
- One or more IOP-lowering agents will be administered systemically, or if in a topical formulation, at a concentration of between 0.001 and 5.0 wt %, preferably, 0.01 to 2.5 wt %, but preferably 0.001-0.005 for prostaglandins.
- The IOP-lowering compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference.
- In addition to the above-described principal ingredients, the IOP-lowering compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents. Examples of suitable antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Polyquad® and other agents equally well-known to those skilled in the art. Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt %. Examples of suitable agents which may be used to adjust the tonicity or osmolality of the formulations include: sodium chloride, potassium chloride, mannitol, dextrose, glycerin, and propylene glycol. Such agents, if utilized, will typically be employed in an amount between about 0.1 and about 10.0 wt %.
- As will be appreciated by those skilled in the art, the compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts. The compositions are preferably aqueous suspensions or solutions.
- The compositions of the present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions and solid compositions or devices.
- The first class, substantially non-aqueous liquids, comprise an IOP-lowering agent and a second agent (“drug combination”) dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
- The second class, semi-solid compositions, comprise an IOP-lowering agent dissolved or suspended in one or more of the following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base, such as Plastibase(g; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
- The third class, solid compositions or devices, include non-erodible devices which are inserted into the conjunctival sac of the eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on). Especially preferred are the bioerodible inserts described and detailed in U.S. Pat. No. 4,540,408 (Lloyd) and U.S. Pat. No. 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol. The entire contents of these two patents are incorporated herein by reference.
- The present invention is also directed to methods of treating persons with glaucoma or ocular hypertension. At least one glutamate antagonist will be administered systemically and at least one IOP-lowering composition described above is applied topically to the affected eye(s) of the patient. The frequency and amount of dosage will be determined by the clinician based on various clinical factors. The methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day.
- The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/267,966 US6441047B2 (en) | 1995-11-17 | 1999-03-12 | Combination therapy for treating glaucoma |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56005595A | 1995-11-17 | 1995-11-17 | |
US08/919,882 US5883108A (en) | 1995-11-17 | 1997-08-28 | Combination therapy for treating glaucoma |
US09/267,966 US6441047B2 (en) | 1995-11-17 | 1999-03-12 | Combination therapy for treating glaucoma |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/919,882 Continuation-In-Part US5883108A (en) | 1995-11-17 | 1997-08-28 | Combination therapy for treating glaucoma |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010047012A1 true US20010047012A1 (en) | 2001-11-29 |
US6441047B2 US6441047B2 (en) | 2002-08-27 |
Family
ID=27072237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/267,966 Expired - Fee Related US6441047B2 (en) | 1995-11-17 | 1999-03-12 | Combination therapy for treating glaucoma |
Country Status (1)
Country | Link |
---|---|
US (1) | US6441047B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
US20040009222A1 (en) * | 2002-05-07 | 2004-01-15 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
US20040176341A1 (en) * | 2002-05-07 | 2004-09-09 | Kang-Jye Chou | Injectable sustained release delivery devices |
US20090220516A1 (en) * | 2005-06-22 | 2009-09-03 | Alan Laties | Neuroprotection of retinal ganglion cells |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US10028657B2 (en) | 2015-05-22 | 2018-07-24 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
US10137239B2 (en) | 2011-06-02 | 2018-11-27 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
US10258809B2 (en) | 2015-04-24 | 2019-04-16 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
US10350111B2 (en) | 2014-10-27 | 2019-07-16 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
US11179576B2 (en) | 2010-03-19 | 2021-11-23 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
EP2481412B1 (en) * | 2004-05-25 | 2017-09-27 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
EP2377569A1 (en) | 2004-07-02 | 2011-10-19 | QLT Plug Delivery, Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
EP1957986B1 (en) * | 2005-11-22 | 2017-05-24 | McGill University | Intraocular pressure-regulated early genes and uses thereof |
WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
CN103393483B (en) | 2006-03-31 | 2016-08-24 | 玛提治疗有限公司 | Medicine release method, structure and composition for nose tear system |
EP3372205A1 (en) | 2007-09-07 | 2018-09-12 | Mati Therapeutics Inc. | Lacrimal implant detection |
US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
CN102724951A (en) | 2009-11-09 | 2012-10-10 | 阿勒根公司 | Compositions and methods for stimulating hair growth |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
KR20150058551A (en) | 2010-03-26 | 2015-05-28 | 갈데르마 리써어치 앤드 디벨로프먼트 | Improved methods and compositions for safe and effective treatment of telangiectasia |
MX2012010824A (en) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Improved methods and compositions for safe and effective treatment of erythema. |
EP2629757A2 (en) | 2010-10-21 | 2013-08-28 | Galderma S.A. | Brimonidine gel compositions and methods of use |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
FR3043555B1 (en) * | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | MIRABEGRON FOR THE TREATMENT OF RETINAL DISEASES |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ200429A (en) | 1981-04-30 | 1984-10-19 | Smith & Nephew Ass | Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye |
US4730013A (en) | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
FR2534580A1 (en) | 1982-10-13 | 1984-04-20 | Synthelabo | PHENYL-1 PIPERIDINO-2 PROPANOL DERIVATIVES, THEIR PREPARATION, AND MEDICINES THAT CONTAIN THEM |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US4797413A (en) | 1986-05-14 | 1989-01-10 | Merck & Co., Inc. | Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use |
DE3510978A1 (en) | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | NEW 9-HALOGEN PROSTAGLANDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
EP0299914B2 (en) | 1987-07-17 | 2003-04-23 | Schering Aktiengesellschaft | 9-Halogen (Z) prostaglandin derivatives, process for their production and their use as medicines |
US5321128A (en) | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5093329A (en) | 1990-03-12 | 1992-03-03 | Allergan, Inc. | Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives |
US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
US5238961A (en) | 1990-06-14 | 1993-08-24 | Allergan, Inc. | Pgf 1-alcohols and their use as ocular hypotensives |
US5262437A (en) | 1990-12-10 | 1993-11-16 | Allergan, Inc. | Homo-prostaglandin derivatives as ocular hypotensives |
JP2594486B2 (en) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | Topical ophthalmic composition |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5385945A (en) | 1992-10-21 | 1995-01-31 | Allergan, Inc. | 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
US5328933A (en) | 1992-10-28 | 1994-07-12 | Allergan, Inc. | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues |
US5312842A (en) | 1992-10-30 | 1994-05-17 | Allergan, Inc. | Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5545665A (en) | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
-
1999
- 1999-03-12 US US09/267,966 patent/US6441047B2/en not_active Expired - Fee Related
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
US20040009222A1 (en) * | 2002-05-07 | 2004-01-15 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
US20040176341A1 (en) * | 2002-05-07 | 2004-09-09 | Kang-Jye Chou | Injectable sustained release delivery devices |
US20080063687A1 (en) * | 2002-05-07 | 2008-03-13 | Kang-Jye Chou | Injectable sustained release delivery devices |
US20190201324A1 (en) * | 2002-05-07 | 2019-07-04 | EyePoint Pharmaceuticals, Inc. | Injectable sustained release delivery devices |
US20090220516A1 (en) * | 2005-06-22 | 2009-09-03 | Alan Laties | Neuroprotection of retinal ganglion cells |
US8455494B2 (en) | 2009-05-22 | 2013-06-04 | Hek Development, Llc | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US11179576B2 (en) | 2010-03-19 | 2021-11-23 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
US10137239B2 (en) | 2011-06-02 | 2018-11-27 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
US10350111B2 (en) | 2014-10-27 | 2019-07-16 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
US11219553B2 (en) | 2014-10-27 | 2022-01-11 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
US10258809B2 (en) | 2015-04-24 | 2019-04-16 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
US11167149B2 (en) | 2015-04-24 | 2021-11-09 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
US10028657B2 (en) | 2015-05-22 | 2018-07-24 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
Also Published As
Publication number | Publication date |
---|---|
US6441047B2 (en) | 2002-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6441047B2 (en) | Combination therapy for treating glaucoma | |
WO2000054810A1 (en) | Combination therapy for treating glaucoma | |
US6664286B1 (en) | Serotonergic 5ht2 agonists for treating glaucoma | |
KR100452715B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ischemia | |
EP1541151A1 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | |
AU704938B2 (en) | Combination therapy for treating glaucoma | |
US6486208B1 (en) | Sustained release, and comfortable opthalmic composition and method for ocular therapy | |
US6264935B1 (en) | Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum | |
US5438060A (en) | Method of reducing elevated intraocular pressure | |
US6545045B1 (en) | Prostaglandin E agonists for treatment of glaucoma | |
US6172054B1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
EP1267847B1 (en) | 5ht 2 agonists for controlling iop and treating glaucoma | |
US6200990B1 (en) | Neuroprotective agents having antioxidant and NMDA antagonist activity | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
EP1647274A1 (en) | Remedy for pruritus comprising piperidine derivative as the active ingredient | |
JP4300347B2 (en) | Glaucoma treatment agent consisting of bunazosin and prostaglandins | |
EP3730137B1 (en) | Therapeutic agent for glaucoma comprising an fp agonist and timolol | |
US5308849A (en) | Method of reducing elevated intraocular pressure | |
AU2004214563A1 (en) | Combination therapy for treating glaucoma | |
AU2001217709B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
US6927233B1 (en) | 5ht2 agonists for controlling IOP and treating glaucoma | |
AU2001217709A1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
Mealy et al. | Ophthalmic Drugs | |
EP0277814B1 (en) | Anti-glaucoma use of trifluoromethanesulfonamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALCON LABORATORIES, INC, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DESANTIS, LOUIS JR.;REEL/FRAME:009831/0641 Effective date: 19990312 |
|
AS | Assignment |
Owner name: ALCON MANUFACTURING, LTD., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON LABORATORIES, INC.;REEL/FRAME:011667/0559 Effective date: 20010322 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: ALCON RESEARCH, LTD., TEXAS Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729 Effective date: 20080101 Owner name: ALCON RESEARCH, LTD.,TEXAS Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729 Effective date: 20080101 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100827 |